



Providing Individualized Treatment Strategies for Schizophrenia: Lessons from CATIE

Release Date: March 13, 2006

Credit Expiration Date: May 10, 2007

This activity offers CE credit for:

- Physicians (CME)
- Nurses (CNE)
- Psychologists (CEP)
- Social Workers (NASW)
- Case Managers (CCMC)
- Pharmacists (CPE)

FACULTY

Jeffrey A. Lieberman, MD
 Chairman, Department of Psychiatry
 College of Physicians and Surgeons,
 Columbia University
 Director, New York State Psychiatric
 Institute
 Director, Lieber Center for Schizophrenia
 Research
 Psychiatrist-in-Chief at New York
 Presbyterian Hospital & Columbia
 University Medical Center
 New York, NY

Scott Stroup, MD, MPH
 Associate Professor of Psychiatry
 Adjunct Associate Professor of Social
 Medicine
 University of North Carolina-Chapel Hill
 Chapel Hill, NC

For more information or to register for this FREE one-hour activity, please visit www.psychcme.net or call 877.CME.PROS.

For fastest service:

1. Complete form on following page.
2. Check date/time you prefer.
3. FAX form to 240.243.1033.

Presented by



This continuing education activity is provided by



Statement of Need

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial has provided, for the first time, detailed information comparing the efficacy and side effects of existing treatments for schizophrenia. This NIMH-sponsored study assessed 1,460 people between the ages of 18 and 65 who met DSM-IV criteria for schizophrenia. Participants were recruited from the community at large, assigned to interventions already in relatively widespread use, and followed for 18 months. If at any time during the trial an assigned medication was ineffective or not well tolerated, patients were re-randomized to other treatment pathways. To emulate real-world patterns of schizophrenia, CATIE included people with medical comorbidities, substance use disorders, and those currently treated with other medications. Data collection in the study was completed in December 2004, with the initial analysis published in September 2005. The primary outcome of CATIE is all-cause treatment discontinuation, an important clinical endpoint that reflects both clinician and patient judgments about efficacy and tolerability. Secondary outcome measures of CATIE include symptoms, side effects, neurocognitive functioning, and cost-effectiveness. In this evidence-based psychCME activity, CATIE researchers will expand on the initial outcome data, emphasize the importance of providing individualized treatment strategies for patients with schizophrenia, and offer a contextual framework for making responsible, real-world decisions about treating these challenging patients.

Lieberman J, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209-1223.

Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. *Schizophr Bull* 2003;29:15-31.

Activity Goal

To disseminate current and clinically relevant information about the efficacy and side effects of different agents used to treat schizophrenia.

Learning Objectives

- At the end of this CE activity, participants should be able to:
- Compare and contrast the efficacy of the various agents in the CATIE trial.
 - Apply a contextual framework to the CATIE results as new data become available.
 - Identify the factors involved in providing individualized treatment strategies for patients with schizophrenia.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.

Commercial Support

CME Outfitters, LLC, gratefully acknowledges an educational grant from Eli Lilly and Company in support of this CE activity.

Credit Information

CME Credit (Physicians): CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses): This Educational Activity is presented by CME Outfitters, LLC, which has been approved as a provider of continuing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. It has been assigned code 5UYSJZ-PRV-0491. 1.2 contact hours (Pharmacology)

CEP Credit (Psychologists): CME Outfitters, LLC, is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters, LLC, maintains responsibility for this program and its content. (1.0 CE credits)

NASW Credit (Social Workers): This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.

CCMC Credit (Certified Case Managers): This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists): CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)

Universal Program Number:
 376-999-06-007-L01 (live interactive session)
 376-999-06-007-H01 (recorded activities)

To receive credit, participants must review all activity materials in their entirety, score 70% or above on a post-test, and fully complete and return both the credit request form and activity evaluation. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.

TK-009-031306-11



**Providing Individualized Treatment Strategies
for Schizophrenia: Lessons from CATIE**

- March 13, 2006**
1:15 p.m.–2:15 p.m. ET
12:15 p.m.–1:15 p.m. CT
11:15 a.m.–12:15 p.m. MT
10:15 a.m.–11:15 a.m. PT
- March 17, 2006**
3:15 p.m.–4:15 p.m. ET
2:15 p.m.–3:15 p.m. CT
1:15 p.m.–2:15 p.m. MT
12:15 p.m.–1:15 p.m. PT
- March 20, 2006**
8:15 p.m.–9:15 p.m. ET
7:15 p.m.–8:15 p.m. CT
6:15 p.m.–7:15 p.m. MT
5:15 p.m.–6:15 p.m. PT
- April 4, 2006**
2:15 p.m.–3:15 p.m. ET
1:15 p.m.–2:15 p.m. CT
12:15 p.m.–1:15 p.m. MT
11:15 a.m.–12:15 p.m. PT
- April 6, 2006**
12:15 p.m.–1:15 p.m. ET
11:15 a.m.–12:15 p.m. CT
10:15 a.m.–11:15 a.m. MT
9:15 a.m.–10:15 a.m. PT
- April 7, 2006**
12:15 p.m.–1:15 p.m. ET
11:15 a.m.–12:15 p.m. CT
10:15 a.m.–11:15 a.m. MT
9:15 a.m.–10:15 a.m. PT
- April 11, 2006**
12:15 p.m.–1:15 p.m. ET
11:15 a.m.–12:15 p.m. CT
10:15 a.m.–11:15 a.m. MT
9:15 a.m.–10:15 a.m. PT
- April 18, 2006**
1:15 p.m.–2:15 p.m. ET
12:15 p.m.–1:15 p.m. CT
11:15 a.m.–12:15 p.m. MT
10:15 a.m.–11:15 a.m. PT
- April 25, 2006**
12:15 p.m.–1:15 p.m. ET
11:15 a.m.–12:15 p.m. CT
10:15 a.m.–11:15 a.m. MT
9:15 a.m.–10:15 a.m. PT
- April 26, 2006**
5:15 p.m.–6:15 p.m. ET
4:15 p.m.–5:15 p.m. CT
3:15 p.m.–4:15 p.m. MT
2:15 p.m.–3:15 p.m. PT
- May 8, 2006**
5:15 p.m.–6:15 p.m. ET
4:15 p.m.–5:15 p.m. CT
3:15 p.m.–4:15 p.m. MT
2:15 p.m.–3:15 p.m. PT
- May 10, 2006**
12:15 p.m.–1:15 p.m. ET
11:15 a.m.–12:15 p.m. CT
10:15 a.m.–11:15 a.m. MT
9:15 a.m.–10:15 a.m. PT

FAX completed form to **240.243.1033**

Please send me a free CD-ROM of this CE activity.

Name: _____ # of Participants: _____

Community Mental Health State Mental Health
 Private Practice Primary Care Other:

Degree: _____ Practice Setting: _____

Address: _____

City/State/ZIP: _____

Phone: _____ Fax: _____

Email: _____